David M Briere, Shuai Li, Andrew Calinisan, Niranjan Sudhakar, Ruth Aranda, Lauren Hargis, David H Peng, Jiehui Deng, Lars D Engstrom, Jill Hallin, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Kwok-Kin Wong, James G Christensen, Peter Olson
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non-small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12C mutations are smoking-associated transversion mutations associated with high tumor mutation burden, PD-L1 positivity, and an immunosuppressive tumor microenvironment. To evaluate the potential of MRTX849 to augment CIT, its impact on immune signaling and response to CIT was evaluated...
June 2021: Molecular Cancer Therapeutics